PP
BPMC

Paloma Partners’s Blueprint Medicines BPMC Stock Holding History

Paloma Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,701
Closed -$377K – 1309
2019
Q4 		$377K Buy
+4,701
New +$352K 0.01% 1593
2019
Q2 		– Sell
-6,959
Closed -$557K – 1743
2019
Q1 		$557K Buy
+6,959
New +$514K 0.01% 1004

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Paloma Partners's BPMC Position: Q1 2020 in Review

Paloma Partners sold out of Blueprint Medicines (BPMC) in Q1 2020, closing a stake of 4,701 shares — an estimated $377K sold.

Paloma Partners first reported a position in BPMC in Q1 2019 and held it in 2 quarters. The position peaked at $557K in Q1 2019. 213 funds tracked by Wall St. Rank hold BPMC as of Q1 2020.

  • Paloma Partners reported no remaining Blueprint Medicines position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 4,701 Blueprint Medicines shares in Q1 2020, an estimated $377K.
  • Paloma Partners first reported a position in Blueprint Medicines in Q1 2019 and held it in 2 quarters.
  • Paloma Partners's Blueprint Medicines position peaked at $557K in Q1 2019.
  • 213 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.